About
Regorafenib is an oral multi-kinase inhibitor that targets various kinases involved in oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. It inhibits several receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, KIT, RET, PDGFR-beta, and FGFR, as well as the intracellular kinase BRAF. By blocking these pathways, regorafenib disrupts tumor cell proliferation, inhibits the formation of new blood vessels that supply tumors, and modulates the tumor's surrounding environment, ultimately leading to tumor growth inhibition and cell death. Its broad spectrum of kinase inhibition makes it effective against several advanced solid tumors.
Regorafenib is indicated for the treatment of metastatic colorectal cancer (mCRC) that has progressed on prior therapies, unresectable or metastatic gastrointestinal stromal tumors (GIST) after prior treatment with imatinib and sunitinib, and hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. It represents an important option for patients with refractory cancers, extending progression-free and overall survival in these challenging settings. Close monitoring for adverse events, particularly hand-foot skin reaction and hypertension, is crucial.
Uses
- Treatment of metastatic colorectal cancer (mCRC) after prior therapies.
- Treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST).
- Treatment of hepatocellular carcinoma (HCC) after sorafenib.
- For patients with progressive disease despite standard treatments.
Directions For Use
Take orally once daily for 21 days, followed by a 7-day rest period, as directed by your oncologist. Take after a light meal.
Benefits
- Targets multiple pathways in cancer development.
- Inhibits tumor angiogenesis and proliferation.
- Effective in refractory metastatic cancers.
- Oral administration for patient convenience.
- Extends progression-free and overall survival.
- Offers a treatment option after other therapies fail.
Side Effects
- Hand-foot skin reaction (palmar-plantar erythrodysesthesia)
- Fatigue
- Diarrhea
- Decreased appetite
- Hypertension
- Dysphonia
- Rash
- Weight loss
- Abdominal pain
- Nausea
- Hemorrhage
- Liver toxicity
Safety Measures
- Alcohol - No specific contraindication, but alcohol may exacerbate liver toxicity or gastrointestinal side effects.
- Pregnancy - May cause fetal harm; avoid use during pregnancy. Advise women of reproductive potential to use effective contraception.
- Breastfeeding - Not recommended during breastfeeding as it may pass into breast milk and harm the infant. Advise against breastfeeding for 2 weeks after the last dose.
- Liver - Use with extreme caution in patients with hepatic impairment; monitor liver function closely. Dose adjustment may be necessary.
- Kidney - No dose adjustment is required for mild to moderate renal impairment; use with caution in severe impairment.
- Lung - Monitor for new or worsening pulmonary symptoms, including interstitial lung disease, though rare.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!